Knowledge Library

WuXi AppTec Oligonucleotide Biology Platform

WuXi Biology oligonucleotide capabilities Sequence design Knockdown effect incell lines and primary cells (transfection d f uptake) Splicing analysis Functional assays Other assays: Tm determination Cytotoxicity lmmunotoxicity Off-target effect “Humanized” mouse models Transgenic, HDI and AAV mouse models NHP models Short and longterm KD efficacy/ harmacology readouts GalNAc-ASGPR delivery system SPR screening Customized assays for …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Candidate Selection Cell-based Assays Discovery Chemistry Gene Manipulation Gene Therapies Hit-to-Lead in vivo Pharmacology Lead Optimization Liver Diseases Oligonucleotides Rare Diseases Safety and Early Toxicity Target-Specific Assays

VIEW

How Does It Work? | RNAi

As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. Protein malfunctions cause many diseases, but a new approach is emerging …Read More >

Resource Type: Video
Resource Topic: Autoimmune and Inflammatory Diseases Cardiovascular & Metabolic Diseases Central Nervous System & Pain DRUG DISCOVERY AND INNOVATION Gene Manipulation Gene Therapies Liver Diseases Metabolic Diseases Oligonucleotides Oncology Ophthalmology Rare Diseases Target Identification and Validation

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics CRISPR/Cas9 Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Manipulation Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis

Resource Type: Webinar
Resource Topic: Biomarkers Lead Optimization Liver Diseases Metabolic Diseases NASH

VIEW

Novel Strategies to Accelerate Discovery of Translatable Therapeutic Targets

Resource Type: Webinar
Resource Topic: Biomarkers Hit Finding Hit-to-Lead in silico services Liver Diseases Oncology Target Identification and Validation

VIEW

Quantitative Histopathology of Fibrosis in an Animal Model of NASH

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >

Resource Type: Article
Resource Topic: Biomarkers Candidate Selection Clinical Bioanalysis Liver Diseases Metabolic Diseases NASH

VIEW